Navigation Links
Hormone therapy associated with reduced colorectal cancer risk
Date:1/7/2009

PHILADELPHIA The combination of estrogen plus progestin, which women stopped taking in droves following the news that it may increase their risk of breast cancer, may decrease their risk of colorectal cancer, according to a report published in the January issue of Cancer Epidemiology, Biomarkers and Prevention, a journal of the American Association for Cancer Research.

"Compared to women who had never taken these hormones, the use of estrogen plus progestin was associated with a reduced risk of colorectal cancer," said Jill R. Johnson, M.P.H., a doctoral student at the University of Minnesota School of Public Health.

The largest risk reduction, approximately 45 percent, was seen among women who had completed use of estrogen plus progestin five or more years previously.

Johnson and her colleagues extracted data from 56,733 postmenopausal women who participated in the Breast Cancer Detection Demonstration Project follow-up study. Hormone therapy use and other risk factors were ascertained through telephone interviews and mailed questionnaires between 1979 and 1998. During an average 15 years of follow-up, Johnson and colleagues identified 960 new cases of colorectal cancer in this population.

Any use of estrogen therapy was associated with a 17 percent reduced risk in colorectal cancer. Among those who used estrogen, the largest reductions were seen among those who were current users (25 percent reduced risk) and users of ten or more years duration (26 percent reduced risk).

Researchers also found a 22 percent reduced risk among those who had ever used estrogen plus progestin in combination. They further found a 36 percent reduction in risk among those who had used progestin sequentially or less than 15 days per month. Past users of estrogen plus progestin, who had stopped at least five years ago, had a 45 percent risk reduction.

Although Johnson's study was not designed to look at biological mecha
'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Food can affect a cell in the same way hormones do
2. Children distressed by family fighting have higher stress hormones
3. Apelin hormone injections powerfully lower blood sugar
4. Birth control has long-term effect on hormone exposure
5. Sex hormones link to heart risk
6. Plant steroids offer new paradigm for how hormones work
7. Prostate cancer vaccines more effective with hormone therapy
8. Growth hormones link to starvation may be clue to increasing life span, researchers find
9. High hormone levels in seabird chicks prepare them to kill their siblings
10. Scientists find potential protein biomarkers for growth hormone
11. Hunger hormone: Makes food more attractive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/6/2015)... and TELTOW, Germany , ... 2015 Siggraph Conference, SensoMotoric Instruments (SMI) shows ... reality , based on Epson,s Moverio BT-200 ... tracking platform. With this new solution, unprecedented quality and ... hands-free interaction with context-sensitive displays. For the first time, ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors ... growth in applications, penetration into newer sectors, and development ... The global biosensors space has seen the entry of ... market so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ... Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... Den 10. internationale konference om Genomik (ICG-10, ... - 25. oktober i Shenzhen , ... i år. Siden starten i 2006 er ICB blevet ... og er en af de mest dynamiske, entusiastiske og ... nylige gennembrud og fremskridt inden for ,omik,-forskning, som yderligere ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... traditional French and Lady Gaga,s sophisticated designs, manicured nails have ... just pretty when nails appeared on all fingers and ... led to the development of critical functions, including finger pads ... whether it,s a nail polish brush or remover to prepare ...
... of mammary gland biology are essential in the fight ... as an Experimental Model , this organ represents an ... processes that occur throughout the body. The branching morphogenesis ... pregnancy, for example, recapitulate steps that occur in many ...
... roads as weed highways, and chemical warfare between alien and native ... in NeoBiota a new open-access, peer-reviewed, rapid ... Pensoft Publishers continuing the former NeoBiota Proceedings ... Khn from the Helmholtz Centre for Environmental Research ...
Cached Biology News:Researchers discover oldest evidence of nails in modern primates 2Researchers discover oldest evidence of nails in modern primates 3Open minded and open access: NeoBiota, a new publishing platform for invasion biologists 2Open minded and open access: NeoBiota, a new publishing platform for invasion biologists 3
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's web-based ... the product choices to a manageable shortlist of bench and floor scales and ... that fit best with the customer’s industry and application. , Side-by-side product ...
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
(Date:8/26/2015)... 2015  Platform therapeutic company Symic Biomedical, Inc. ... $1.5M Phase II SBIR grant from the National ... therapeutic agent to reduce arteriovenous fistula (AVF) failures, ... renal disease (ESRD) patients undergoing hemodialysis. The two-year ... and Digestive and Kidney Diseases (NIDDK), will allow ...
(Date:8/26/2015)... 2015 After litigating and negotiating patent ... to P2i United States patent RE43,651 ... the United States without any admission ... either party. As a result of the parties, settlement, the ... California dismissed the case without prejudice. ...
Breaking Biology Technology:METTLER TOLEDO Updates Online Scale Selection Tool 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3P2i Settles United States Litigation 2
... at, http://www.StopAfib.org, announces that September is Atrial Fibrillation,Month ... afib or AF., Once considered benign, this common ... stroke. Every five minutes, someone in the,U.S. has a ... and the #1 cause of,permanent disability, and takes a ...
... ... 2 -, BRISBANE, Calif., Sept. 2 InterMune, Inc.,(Nasdaq: ... $15 million,development milestone under its development collaboration with Roche for,the ... as R7227 at Roche), currently in a Phase 1b clinical ...
... SAN MATEO, Calif., Sept. 2 NeurogesX, Inc.,(Nasdaq: ... developing and,commercializing novel pain management therapies, announced today ... scheduled to,present at the Morgan Stanley Global Healthcare ... 9, 2008. Mr. DiTonno and Stephen Ghiglieri,Chief Financial ...
Cached Biology Technology:Atrial Fibrillation Month - StopAfib.org Announces September Focus on Life-Threatening Irregular Heartbeat 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 3InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 4NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference 2NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference 3
... FilterMate is a compact, versatile system that ... 96- or 24-well microplates into a solid ... liquid scintillation and gamma counter. The FilterMate ... for applications such as cell proliferation, receptor ...
... a single fragment based screening project: , ... 96 shape-diverse mixtures of 4 (5 uL each) ... structure refinement , Individual compounds are dissolved ... ca. 50 mM. Supplied in 5 96-well trays. ...
... (Catalog number SCR004) is a specific and ... ES cell differentiation by the determination of ... are the monoclonal antibodies TRA-2-49 (Catalog Number ... permit the detection of Liver / Bone ...
Rabbit polyclonal to Shigella Immunogen: Mixture of S. boydii, S. flexneri & S. dysenteriae....
Biology Products: